Ethicon Seeks To Expand Access To Bariatric Surgery, Increase Product Market Share Through Investment

With nearly 30% of the world’s population overweight or obese, Johnson & Johnson's Ethicon division is seeking to expand patients’ access to bariatric surgery in certain countries by funding studies that demonstrate its benefits. By convincing payors in these countries that bariatric surgery addresses not only weight loss but also metabolic diseases, Ethicon hopes to increase its products' market share in these countries, too.

As obesity and metabolic diseases balloon worldwide, Ethicon Inc./Johnson & Johnson is hoping to grow its products’ market share and to expand access to bariatric surgery to patients in countries where access is limited due to a variety of factors, by funding clinical research. In a market that has been flat in recent years, Ethicon hopes that by funding these investigations, it will convince payors in a handful of countries that the return on investment for the cost of bariatric surgery outweighs the cost of treating obesity-related disease.

On June 30, Ethicon announced a $3.2 million investment in clinical research to “better understand how earlier surgical intervention may improve conditions such as obesity and type 2 diabetes,” the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Surgical Procedures

Bone Surgery Startup Surgify Medical Raises $7.9m

 

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

SS Innovations Files For De Novo For SSi Mantra 3 Surgical Robotic System For Multispecialty Indications

 
• By 

SS Innovations announced plans to file a de novo application with the US FDA for its SSi Mantra 3 surgical robot, already approved for marketing in six countries. The Florida-based firm also plans to pursue the CE mark for European commercialization.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

More from Surgery

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

AAOS 2025 Orthopedic Roundup: J&J Velys UKA, Stryker Mako 4, Materialise, Canary Medical

 
• By 

At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.